Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In July 2021, we entered into clinical collaboration with Merck, a leader in immuno-oncology. The clinical collaboration and supply agreement includes open-label, dose escalation and expansion clinical studies to evaluate our anti-CTLA-4 mAb product candidate, ADG126 in combination with pembrolizumab for patients with advanced/metastatic solid tumors. Under terms of the agreement, Merck provides pembrolizumab and input on our clinical trials evaluating pembrolizumab in combination with ADG126”
FILING20-F0001104659-26-038612cik 0001818838
“In December 2022, we announced a clinical trial collaboration agreement with Roche to evaluate the triple combination of our ADG126 with Roche's atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC).”
FILING20-F0001104659-26-038612cik 0001818838
“Our technology licensing agreements with Sanofi and Exelixis focus on developing antibody-based therapeutics against tumor targets using our SAFEbody technology. In 2025 - Sanofi exercised its option for a third SAFEbody discovery program, building on the 2022 collaboration.”
FILING20-F0001104659-26-038612cik 0001818838
“We advanced a third masked ADC program with Exelixis against a solid tumor target, building on the 2021 collaboration.”
FILING20-F0001104659-26-038612cik 0001818838
“We partnered with Third Arc Bio to develop two masked CD3 T cell engagers, expanding SAFEbody into next-generation T cell therapies.”
FILING20-F0001104659-26-038612cik 0001818838
“We collaborated with ConjugateBio on bispecific ADCs using Adagene-derived antibody, further demonstrating scalable platform potential.”
FILING20-F0001104659-26-038612cik 0001818838
“We have out-licensed the Greater China rights for two antibody candidates to Sanjin and its affiliates.”
FILING20-F0001104659-26-038612cik 0001818838
Watchlist prices, news filtered to it, and its next report on your desk.
Prev close 2.98 · gapped above the open, then crossed back over prior close. High/low 3.39 at 9:30 am ET, 2.95 at 3:30 pm ET.
Adagene Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Manufacturing
Adagene Inc. has 2 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Adagene Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
ADAG (Adagene Inc.) has 2 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: EXEL +2.37%, in healthcare.